Total threshold cytotoxicity of therapeutic antibodies for selective destruction of pathogenic memory T cells: implications for immunotherapy of autoimmune and allergenic disorders

References

• Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20:4–12.
   PubMed Web of Science ®Google Scholar
• Seledtsov VI, Seledtsova GV. A possible role for idiotype/anti-idiotype B-T cell interactions in maintaining immune memory. Front Immunol. 2017;8:409.
   PubMed Web of Science ®Google Scholar
• Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunol Res. 2013;57:12–22.
   PubMed Web of Science ®Google Scholar
• Clark R. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7:269rv1–269rv1.
   PubMed Web of Science ®Google Scholar
• Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002;38:1133–1140.
   PubMed Web of Science ®Google Scholar
• Kontermann R. Dual targeting strategies with bispecific antibodies. Mabs. 2014;4:182–197.
   Web of Science ®Google Scholar
• Bhargava P, Calabresi PA. Novel therapies for memory cells in autoimmune diseases. Clin Exp Immunol. 2015;180:353–360.
   PubMed Web of Science ®Google Scholar
• Moro-García M, Mayo J, Sainz R, et al. Influence of Inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol. 2018;9:339.
   PubMed Web of Science ®Google Scholar
• Farber D, Yudanin N, Restifo N. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2013;14:nri3567.
   Web of Science ®Google Scholar
• Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007;117:1119–1127.
   PubMed Web of Science ®Google Scholar
• Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med. 2010;12:164–178.
   PubMed Web of Science ®Google Scholar
• Seledtsova GV, Ivanova IP, Shishkov AA, et al. Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis. J Immunotoxicol. 2016;13:879–884.
   PubMed Web of Science ®Google Scholar
• Shinoda K, Hirahara K, Nakayama T. Maintenance of pathogenic Th2 cells in allergic disorders. Allergol Int. 2017;66:369–376.
   PubMed Web of Science ®Google Scholar
• Kobezda T, Ghassemi-Nejad S, Mikecz K, et al. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol. 2014;10:160–170.
   PubMed Web of Science ®Google Scholar
• Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013;1:306–316.
   PubMed Web of Science ®Google Scholar
• Rep M, van Oosten BW, Roos MT, et al. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest. 1997;99:2225–2231.
   PubMed Web of Science ®Google Scholar
• Hakulinen J. Complement-mediated killing of cancer cells [PhD thesis]; 2003. Available from: https://helda.helsinki.fi/bitstream/handle/10138/20483/compleme.pdf?sequence=1
   Google Scholar
• Rajasekaran N, Chester C, Yonezawa A, et al. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther. 2015;4:91–100. DOI:10.2147/ITT.S61292
   Google Scholar
• Seledtsov VI, Goncharov AG, Seledtsova GV. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother. 2015;11:851–869.
   PubMed Web of Science ®Google Scholar
• Jones JF, Plotz PH, Segal DM. Complement and cell-mediated lysis of haptenated erythrocytes sensitized with oligomers of rabbit IgG antibody. Mol Immunol. 1979;16:889–897.
   PubMed Web of Science ®Google Scholar
• Keaney M, McPhail S, Jodouín CA, et al. The antibody-dependent cell-mediated cytotoxic reaction. II. The effect of the concentration of anti-target cell antibodies on the identity of the human effector cells. Immunology. 1980;40:205–210.
   PubMed Web of Science ®Google Scholar
• Edwards SW, Morgan BP, Hoy TG, et al. Complement-mediated lysis of pigeon erythrocyte ghosts analysed by flow cytometry. Evidence for the involvement of a ‘threshold’ phenomenon. Biochem J. 1983;216:195–202.
   PubMed Web of Science ®Google Scholar
• Miklós K, Tolnay M, Bazin H, et al. Antibody mediated lysis of hapten-conjugated target cells by macrophages and by complement: the influence of IgG subclass, antibody and hapten density. Mol Immunol. 1992;29:379–384.
   PubMed Web of Science ®Google Scholar
• Murray-Segal L, Gock H, Cowan PJ, et al. Anti-Gal antibody-mediated skin graft rejection requires a threshold level of Gal expression. Xenotransplantation. 2008;15:20–26.
   PubMed Web of Science ®Google Scholar
• Cheresh DA, Honsik CJ, Staffileno LK, et al. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA. 1985;82:5155–5159.
   PubMed Web of Science ®Google Scholar
• Greiner JW, Guadagni F, Hand PH, et al. Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas. Cancer Treat Res. 1990;51:413–432.
   PubMedGoogle Scholar
• Van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12:4027–4035.
   PubMed Web of Science ®Google Scholar
• Lindorfer M, Beum P, Taylor R. CD20 mAb-mediated complement dependent cytotoxicity of tumor cells is enhanced by blocking the action of factor I. Antibodies. 2013;2:598–616.
   Google Scholar
• Tang Y, Lou J, Alpaugh RK, et al. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007;179:2815–2823.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63–73.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar N, Dwiwedi P, et al. Monoclonal antibodies: a review. Curr Clin Pharmacol. 2017. DOI:10.2174/1574884712666170809124728
   Web of Science ®Google Scholar
• Wu H, Liao W, Li Q, et al. Pathogenic role of tissue-resident memory T cells in autoimmune diseases. Autoimmun Rev. 2018. DOI:10.1016/j.autrev.2018.03.014
   Web of Science ®Google Scholar
• Kimura M, Hayashizaki K, Tokoyoda K, et al. Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation. Immunol Rev. 2017;278:87–100.
   PubMed Web of Science ®Google Scholar
• Wang H, Dai Y, Wang J, et al. Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma. J Zhejiang Univ Sci B. 2015;16:622–631.
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti CD20 antibody. Br J Haematol. 2008;140:303–312.
   PubMed Web of Science ®Google Scholar
• Murungi LM, Kamuyu G, Lowe B, et al. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine. 2013;31:3936–3942.
   PubMed Web of Science ®Google Scholar